Browsing by Subject "Sepsis"

Article

Angiotensin converting enzyme (ACE) insertion/deletion (I/D) polymorphism and circulating ACE levels are not associated with outcome in critically ill septic patients

Tsantes, Argirio E.; Tsangaris, I.; Kopterides, Petros; Nikolopoulos, Georgios K.; Kalamara, Eleni; Antonakos, Georgios; Kapsimali, Violetta; Gialeraki, Argiri; Dimopoulou, Ioanna; Orfanos, S.; Dima, Kleanthi; Travlou, Anthi S.; Armaganidis, Apostolos (2012)

Background: In critically ill patients independent studies have shown contradictory findings regarding the prognostic significance of the D/D genotype of the I/D angiotensin converting enzyme (ACE) polymorphism. The study ...

Article

The beginning of personalized medicine in sepsis: Small steps to a bright future

Christaki, Eirini; Giamarellos-Bourboulis, Evangelos J. (2014)

There is a growing recognition that there is a need for a more personalized approach towards sepsis care. In most clinical trials investigating novel therapeutic interventions against sepsis, patients have been considered ...

Article

The complex pathogenesis of bacteremia: From antimicrobial clearance mechanisms to the genetic background of the host

Christaki, Eirini; Giamarellos-Bourboulis, Evangelos J. (2014)

Bacteremia develops when bacteria manage to escape the host immune mechanisms or when the otherwise well-orchestrated immune response fails to control bacterial spread due to inherent or acquired immune defects that are ...

Article

Docetaxel (Taxotere™) is active in non-small-cell lung cancer: A phase II trial of the EORTC early clinical trials group (ECTG)

Cerny, T.; Kaplan, S.; Pavlidis, Nicholas; Schöffski, P.; Epelbaum, R.; Meerbeek, J. van; Wanders, J.; Franklin, H. R.; Kaye, Stanley B. (1994)

In a multicentre trial of the EORTC ECTG we have treated 43 non-pretreated patients with advanced non-small-cell lung cancer (NSCLC) with the new semisynthetic taxoid docetaxel (Taxotere). Six patients were ineligible; of ...

Article

The effect of homocysteine on the clinical outcomes of ventilated patients with severe sepsis

Tsantes, Argirio E.; Tsangaris, I.; Nikolopoulos, Georgios K.; Bagos, Pantelis G.; Kopterides, Petros; Antonakos, Georgios; Dimopoulou, Ioanna; Vrioni, G.; Kapsimali, Violetta; Dima, Kleanthi; Armaganidis, Apostolos; Travlou, Anthi S. (2010)

Background. There is considerable evidence that elevated plasma homocysteine levels are associated with a prothrombotic milieu, whereas activation of the coagulation cascade is an important component of the pathogenesis ...

Article

Estrogen receptor β agonism increases survival in experimentally induced sepsis and ameliorates the genomic sepsis signature: A pharmacogenomic study

Christaki, Eirini; Opal, Steven M.; Jr, James C. Keith; Kessimian, Nubar; Palardy, J. E.; Parejo, N. A.; LaVallie, Edward R.; Racie, L.; Mounts, W.; Malamas, Michael S.; Mewshaw, Richard E.; Harris, Heather A.; Vlasuk, G. P. (2010)

Background. Nonsteroidal agonists have been developed that selectively bind to and activate estrogen receptor β (ERβ) rather than estrogen receptor α (ERα). ERβ is expressed equally in both male and female mammals in ...

Article

Immunomodulatory therapy for sepsis: An update

Christaki, Eirini; Anyfanti, Panagiota; Opal, Steven M. (2011)

Currently the treatment mainstay of sepsis is early and appropriate antibiotic therapy, accompanied by aggressive fluid administration, the use of vasopressors when needed and the prompt initiation of measures to support ...

Article

Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: Accumulating evidence of efficacy, synergy and safety

Lazaridis, G.; Pentheroudakis, George; Pavlidis, Nicholas (2008)

Neoadjuvant chemotherapy is used in non-metastatic breast cancer in order to eradicate micrometastatic deposits early during disease course, as well as in order to decrease tumour bulk and render surgery feasible or ...

Article

Intensified bimonthly cisplatin with bolus 5-fluorouracil, continuous 5-fluorouracil and high-dose leucovorin (LV5FU2) in patients with advanced gastrointestinal carcinomas: A phase I dose-finding and pharmacokinetic study

Bamias, A. T.; Syrigos, K.; Fountzilas, George; Tzamakou, E.; Soulti, K.; Karavasilis, V.; Alamanos, Y. P.; Christodoulou, C.; Pavlidis, Nicholas (2004)

5-Fluorouracil (5FU) and cisplatin are commonly used in the treatment of gastric cancer. Continuous 5FU appears to be more effective and less toxic than bolus administration, while increasing the dose intensity of cisplatin ...

Article

Is the mortality rate for septic shock really decreasing?

Christaki, Eirini; Opal, Steven M. (2008)

Survival rates for patients in septic shock have gradually improved in critical care units worldwide over the last 25 years. Further improvement will be predicated on the discovery of new therapies to disrupt the underlying ...

Article

The kinetics of T regulatory cells in shock: Beyond sepsis

Christaki, Eirini; Patrozou, E. (2010)

During the past decade, there have been an increasing number of studies investigating the precise role of T regulatory cells in human disease. First recognized for their ability to prevent autoimmunity, T regulatory cells ...

Article

A monoclonal antibody against RAGE alters gene expression and is protective in experimental models of sepsis and pneumococcal pneumonia

Christaki, Eirini; Opal, Steven M.; Jr, James C. Keith; Kessimian, Nubar; Palardy, J. E.; Parejo, N. A.; Tan, X. Y.; Piche-Nicholas, N.; Tchistiakova, L.; Vlasuk, G. P.; Shields, K. M.; Feldman, Jeffrey L.; LaVallie, Edward R.; Arai, Maya; Mounts, W.; Pittman, D. D. (2011)

The RAGE (receptor for advanced glycation end products) is believed to play a role in sepsis by perpetuating inflammation. The interaction of RAGE with a variety of host-derived ligands that accumulate during stress and ...

Article

NK and NKT cell depletion alters the outcome of experimental pneumococcal pneumonia: Relationship with regulation of interferon- γ production

Christaki, Eirini; Diza, Evdoxia; Giamarellos-Bourboulis, Evangelos J.; Papadopoulou, Nikoletta; Pistiki, Aikaterini; Droggiti, Dionysia-Irini; Georgitsi, Marianna; Machova, Alzbeta; Lambrelli, Dimitra; Malisiovas, Nicolaos; Nikolaidis, Pavlos; Opal, Steven M. (2014)

Background. Natural killer (NK) and natural killer T (NKT) cells contribute to the innate host defense but their role in bacterial sepsis remains controversial. Methods. C57BL/6 mice were infected intratracheally with 5 × ...

Article

Personalized medicine in sepsis: The coming of age

Christaki, Eirini (2013)

"a there is both the need to discover specific and clinically useful biomarkers in order to diagnose sepsis, define the hosta s immune status, monitor treatment and define prognosis and to develop medications that would ...

Article

Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer

Bamias, A. T.; Papamichael, D.; Syrigos, K.; Pavlidis, Nicholas (2003)

The aim of this phase II study was to investigate the tolerance and efficacy of a second-line irinotecan/ mitomycin C combination in patients with advanced gastric or colorectal cancer, pretreated with 5-fluorouracil. Forty ...

Article

Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG)

Chollet, P.; Schöffski, P.; Weigang-Köhler, K.; Schellens, J. H. M.; Cure, H.; Pavlidis, Nicholas; Grünwald, V.; Boer, R. De; Wanders, J.; Fumoleau, P. (2003)

S-1 is a new oral fluorinated pyrimidine derivate, in which the oral 5-fluorouracil (5-FU) prodrug, tegafur, was combined with two 5-FU-modulating substances, 5-chloro-2,4-dihydroxypyridine (gimeracil), and potassium oxonate ...

Article

Postoperative sepsis in infants below 6 months of age

Kessler, Ulf; Ebneter, Marc; Zachariou, Zacharias; Berger, Steffen (2009)

Background: Sepsis is a threatening postoperative complication especially in small infants. Regarding the advances in perinatal medicine, its incidence is unknown to date. We aimed to investigate the incidence, risk factors, ...

Article

Receptor for advanced glycation end products in bacterial infection: Is there a role for immune modulation of receptor for advanced glycation end products in the treatment of sepsis?

Christaki, Eirini; Lazaridis, Nikolaos; Opal, Steven M. (2012)

Purpose of review: Sepsis is still associated with excess morbidity and mortality worldwide, despite significant advances in critical care medicine. A novel approach is needed in the treatment of sepsis, one that will aim ...

Article

Recombinant interferon ALFA-2A in combination with carboplatin, vinblastine, and bleomycin in the treatment of advanced malignant melanoma

Bafaloukos, Dimitrios; Pavlidis, Nicholas; Fountzilas, George; Skarlos, Dimosthenis V.; Klouvas, G. D.; Makrantonakis, P.; Giannakakis, T.; Tsavaris, N.; Kosmidis, Paraskevas A. (1996)

Thirty-four patients with advanced malignant melanoma were treated with recombinant alpha-interferon (IFN) and chemotherapy consisting of carboplatin, vinblastine, and bleomycin (CVB). CVB was given for four cycles and IFN ...